Incidence and risk factors of warfarin therapy complications in community hospitals, central and eastern regions, Thailand: a retrospective, multicenter, cohort study

Author:

Sombat Benyapha,Tongkaew Sarisa,Nilwaranon Aticha,Mungthin Mathirut,Jongcherdchootrakul Kanlaya,Lertwanichwattana Teeraboon

Abstract

Abstract Objectives Warfarin, like many other anticoagulants, has been linked to an elevated risk of bleeding proportional to the amount of anticoagulation used. Not only was the incidence of bleeding raised by the dosage, but the subtherapeutic international normalized ratio (INR) was also associated with increased thrombotic events. This retrospective cohort and multi-center study evaluated the incidence and risk factors of warfarin therapy complications in community hospitals in Thailand’s central and eastern regions from 2016 to 2021. Results Among 335 patients (683.90 person-year of follow-up), The incidence rate of warfarin complications was 4.91 events per 100 person-year. The independent factor associated with warfarin therapy complications was propranolol prescription (Adjusted RR: 2.29, 95%CI: 1.12–4.71). The secondary analysis was divided according to the outcome of the major bleeding and thromboembolic event. Major bleeding events, hypertension (Adjusted RR: 0.40, 95%CI: 0.17–0.95), amiodarone prescription (Adjusted RR: 5.11, 95%CI: 1.08–24.15), and propranolol prescription (Adjusted RR: 2.86, 95%CI: 1.19–6.83) were the independent risk factors. While in the major thrombotic event, non-steroidal anti-inflammatory drugs (NSAIDs) prescription was an independent factor (Adjusted RR: 10.65, 95%CI: 1.26–90.35).

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference36 articles.

1. Telles-Garcia N, Dahal K, Kocherla C, Lip GYH, Reddy P, Dominic P. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol [Internet]. 2018;268:143–8. Available from: https://doi.org/10.1016/j.ijcard.2018.04.034

2. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy - antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):e44S-e88S.

3. Zhao YJ, Lin L, Zhou HJ, Tan KT, Chew AP, Foo CG et al. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. Int J Cardiol [Internet]. 2016;220:794–801. Available from: https://doi.org/10.1016/j.ijcard.2016.06.087

4. Jarungsuccess S, Taerakun S. Cost-utility analysis of oral anticoagulants for Nonvalvular Atrial fibrillation patients at the police general hospital, Bangkok, Thailand. Clin Ther [Internet]. 2014;36(10):1389–1394.e4. Available from: https://doi.org/10.1016/j.clinthera.2014.08.016

5. Ng SS, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand. Thromb Res [Internet]. 2020;185:63–71. Available from: https://doi.org/10.1016/j.thromres.2019.11.012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3